SCHEMBL6507397

SCHEMBL6507397

NC(=O)Nc1cn(-c2cccc(-c3cncnc3)c2)nc1C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.45
SCN9A Q15858 1/20 0.44
IRAK4 Q9NWZ3 9/20 0.43
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 1/20 0.39
TBK1 Q9UHD2 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
POLB P06746 1/20 0.38
PDE10A Q9Y233 1/20 0.37
MITF O75030 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
IKBKB O14920 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465740 0.87 IRAK4 (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6508710 0.86 IKBKB (0.47) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6467349 0.86 ITK (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6503522 0.86 ITK (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6502412 0.85 SCN9A (0.47) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6499548 0.85 ITK (0.45) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6501255 0.85 ITK (0.45) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6505904 0.85 ITK (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6499924 0.85 IKBKB (0.48) ITKSCN9AIRAK4LMNASMN1; SMN2
SCHEMBL6470464 0.84 KDM4E (0.46) ITKSCN9AIRAK4LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases BAYER HEALTHCARE AG (DE) 2005-01-13 US disclosed
WO-1994009002-A1 2-(AZA-9-FLUORENONYL)CARBAPENEM ANTIBACTERIAL AGENTS MERCK & CO., INC. (US) 1994-04-28 WO disclosed
US-5294610-A Staphylococcus; side effect reduction MERCK & CO. INC. (US) 1994-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009820-A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases HTT, HMOX1, SNCA ITK 3063/4885SCN9A 1564/4885IRAK4 3374/4885
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 ITK 4236/4885SCN9A 4159/4885IRAK4 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.